Stability and Acute Toxicity (LD50) Test of Medicinal Filler made from Chicken Liver Supplemented with Silymarin

Background: Chicken liver is a high-protein animal by-product with high palatability for carnivorous animals, particularly cats, making it a promising candidate as a natural medicinal filler. In veterinary pharmaceutics, palatability and safety are critical factors for oral dosage forms. Silymarin is a well-known hepatoprotective compound; however, its incorporation into animal-based fillers requires stability and safety evaluation.

Aims: to evaluate the stability and acute toxicity of chicken liver paste supplemented with silymarin as a potential medication filler for animals.

Methods: Stability tests were conducted on both chicken liver paste without silymarin and paste supplemented with silymarin. Evaluated parameters included organoleptic properties, homogeneity, pH, viscosity, adhesion, and spreadability. Acute toxicity testing (LD₅₀) was performed using twenty-five female rats divided into five groups. The control group received chicken liver paste without silymarin, while treatment groups received silymarin-supplemented paste at doses of 10, 15, and 20 g/kg body weight. Animals were observed for 14 days to assess mortality, clinical signs, body temperature, body weight changes, and hematological parameters.

Results: Stability testing demonstrated that both formulations met standard requirements across all evaluated parameters. No mortality or abnormal clinical signs were observed during the acute toxicity study. Additionally, body temperature, weight gain, and hematological profiles showed no significant differences between control and treatment groups.

Conclusion: Chicken liver paste supplemented with silymarin exhibited good stability and was classified as practically non-toxic, indicating its suitability as a safe and effective medicinal filler for animal use.